Future research should aim at assessing the accuracy of using AAA-1 to predict histology-based NAFLD/NASH/cirrhosis diagnoses, and at defining if AAA-1 could represent actionable therapeutic targets through SGLT-2 inhibition in order to promote the development of precision medicine in the field of NAFLD. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.